Abstract LB240: Preclinical evaluation of ABSK112, a selective and CNS-penetrant compound with strong HER2 inhibitory activity for treating HER2-driven solid tumors
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Bin Shen, Cheng Dai, Shenyan Liu, Cong Li, Jie Wang, Jie Zhang, Manqi Liu, Zhui Chen, Nannan Zhang
Institution: Abbisko Therapeutics Co., Ltd. (China)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409821260